key: cord-1011286-cw5km53l
authors: Wasim, Daanyaal; Alme, Bjørn; Jordal, Stina; Lind Eagan, Tomas Mikal; Tadic, Marijana; Mancia, Giuseppe; Guttormsen, Anne Berit; Saeed, Sahrai
title: Characteristics of the 24-hour ambulatory blood pressure monitoring in a COVID-19 survivor
date: 2021-04-20
journal: Future cardiology
DOI: 10.2217/fca-2020-0235
sha: 9f2c444796dd12d2c8890a5e5dec5bcc42647281
doc_id: 1011286
cord_uid: cw5km53l

COVID-19 infection primarily causes severe pneumonia complicated by acute respiratory distress syndrome and multiorgan failure requiring a ventilator support. We present a case of a 55-year-old male, admitted with COVID-19. He was obese but had no other medical conditions. His blood pressure was measured by his general physician on several occasions in the past, all values being normal (<140/90 mmHg). He developed multiorgan failure, requiring vasopressor and ventilator support for 17 days. A prone positioning improved the arterial oxygenation, and reduced the need for supplemental oxygen. After recovery, he showed persistently elevated blood pressure and sinus tachycardia both in clinic and out-of-clinic. The activation of the renin–angiotensin–aldosterone and sympathetic systems, volume-overload, hyperreninemia and cytokine storm might have contributed to the exaggerated cardiovascular response.

Leucocytes (10**9) 23. 4 Triglycerides (mmol/l) 3.2 † In more than one value, the first value denotes the highest or lowest abnormal value during hospitalization and the second on discharge.

eGFR: Estimated glomerular filtration rate.

15 years in the past, he had his BP measured by his general physician, all measurements being within normal range (<140/90 mmHg). At admission, he had fever (38.5 • C), tachycardia (heart rate of 114 bpm) and was cyanotic with a respiratory rate of 40-60/min and oxygen saturation of 50% while receiving 10 L oxygen on face mask (pO 2 /FiO 2 -index 8-9). His BP was 119/78 mmHg. The results of some essential blood tests are presented in Table 1 . He was diagnosed with COVID-19 following a positive PCR for SARS-CoV-2 infection. His condition rapidly deteriorated as he developed ARDS and was immediately transferred to the ICU, intubated and put on ventilator. A chest x-ray showed severe bilateral pneumonia with patchy infiltration of both lungs, consistent with ARDS. A transthoracic echocardiogram, though quality was poor due to obesity and high-pressure ventilation, showed no sign of regional wall motion abnormalities. Left ventricular (LV) end-diastolic dimension was 5.1 cm and systolic function was normal. Tricuspid annular plane systolic excursion was 1.7 cm (normal ≥1.7 cm) and an estimated systolic pulmonary artery pressure of 50 mmHg.

Based upon an inter-disciplinary discussion, he was treated with azithromycin and a third generation cephalosporin, hydroxychloroquine and IL-1 receptor antagonist. His condition deteriorated further and he developed severe multiorgan failure, including coagulopathy, heart failure and renal failure in addition to severe hypoxemia. He received a vasopressor support with norepinephrine for 15 days, vasopressine for 7 days and epinephrine for 2 days. Hemofiltration was also required. Due to severe and persistent hypoxemia, he was put in prone positioning intermittently for 6 days, after which a gradual improvement of his arterial oxygenation occurred and the need for supplemental oxygen was substantially reduced. He was treated on ventilator in pressure controlled and pressure support mode for 17 days and required positive airway pressure for an additional 8 days. A tracheostomy was performed on day-14. After 26 days in the ICU, he was transferred to the intermediate care ward and stayed there for another 2 weeks. His kidney function gradually recovered without need of further renal replacement therapy. He showed no sign of cognitive decline upon discharge. After a total of 40 days in hospital, he was transferred to a rehabilitation center, where he exhibited persistently elevated BP; on average systolic 160 and diastolic 90-110 mmHg and a sustained tachycardia with a resting heart rate of approximately 100 bpm. He was put on a beta-blocker and referred to an ambulatory 24-hour BP monitoring. This showed a mean 24-hour BP of 142/84 mmHg, daytime 145/86 mmHg and night-time 128/77 mmHg. 83% of systolic and 71% diastolic BP was elevated (≥130/80 mmHg) during 24-hour BP monitoring. He had sustained sinus tachycardia with a mean heart rate of 101 bpm over 24-hours. Although there was a 12% (normal) night-time BP dipping, the BP decline, however, occurred at late night and he had nocturnal hypertension with an exaggerated morning BP surge ( Figure 1A -B). Due to elevated ambulatory BP measurements, he was put on ramipril 2.5 mg.

A follow-up echocardiogram showed normal LV geometry (LV mass index 90 g/m 2 and relative wall thickness 0.42) ( Figure 1C ), complete normalization of systolic LV function (Simpson biplane ejection fraction of 65%) and regression of pulmonary hypertension. Left atrium anterior-posterior diameter was 3.3 cm, and LV end-diastolic diameter was 5.2 and end-systolic diameter 3.4 cm. Right ventricular size and function was normal: basal diameter 3.5 cm and tricuspid annular plane systolic excursion 2.7 cm. There was no sign of tricuspid regurgitation. Transmitral E wave velocity was 0.7 m/s, deceleration time 220 ms and A wave velocity 0.6 m/s. Septal and lateral annular e velocities were 7 cm/s and 10 cm/s, respectively. Filling pressure was normal (E/e ratio of 9). Right ventricular S was 15 cm/s and septal and lateral annular S 8 and 9 cm/s, respectively.

At a 4-months follow-up at his general physician, the BP was 157/107 mmHg. The dose of ramipril was increased to 5 mg.

At the 6-month follow-up, the patient was feeling well, did not have any breathing difficulty at rest and reported having resumed exercise and work. He had achieved BP control with clinic BP of 124/78 mmHg. A lung function test showed marked improvement of pulmonary function compared with the 3-months follow-up: Forced vital capacity of 4.3 l (80%), forced expiratory volume in 1 s (FEV 1 ) 3.57 l (81%) and diffusion capacity (D L CO) 7.1 mmol/kPa.min (65%). A chest x-ray revealed significant regression of the infiltrations in the both lungs compared with chest x-ray taken at discharge. Renal function tests were normal: creatinine 111 μmol/l (60-105), estimated glomerular filtration rate 64 ml/min/1.73 m 2 , sodium 140 mmol/l (137-145) and potassium 4.1 mmol/l (3.5-5.0). A further 1-year follow-up is scheduled.

This case report illustrates two important findings: after survival from a severe life-threatening COVID-19 infection complicated by ARDS and multiple organ failure, our patient became sustained hypertensive throughout the convalescent period; prone positioning contributed to significant improvement of his arterial oxygenation, and the need for supplemental oxygen was substantially reduced due to less mismatch between ventilation and circulation [7] [8] .

After recovery, COVID-19 leads to worsening of hypertension, poor diabetic control and renal damage [2] . Hypertension and obesity are together with male sex common comorbidities and risk factors for unfavorable outcome in patients with COVID-19. Our patient had obesity and probably an underlying masked hypertension. However, the echocardiogram showed normal LV wall thicknesses and chamber dimensions. This excluded the possibility of previous significant hypertension and resultant target organ damage. Furthermore, after recovery from a life-threating COVID-19 infection complicated by severe ARDS and multiple organ failure, he developed sustained hypertension. His BP was persistently elevated both in clinic and out-of-clinic. We speculated the activation of neuro-endocrine hormone pathways, such as renin-aldosterone system and sympathetic system at periphery level in a high-risk patient of metabolic syndrome may have changed his hypertension status from masked to sustained hypertension. Furthermore, inflammation-induced systemic cytokine storm, immunological response, prolonged period of mechanical ventilation and associated sedation, volume-overload, use of inotropic agents, increased adrenergic tone, fever, hypoxia, inflammation, ischemia, vasculitis may also have contributed to an exaggerated cardiovascular response and worsening of hypertension. Although evidence from prospective studies are still not available, preliminary results based upon case series have recently indicated that patients with COVID-19 tend to develop hyperreninemia combined with hypernatremia and hyperchloremia in intensive care [9] . Notably, our patient also developed hypernatremia and hyperchloremia and acute kidney injury during intensive care. However, renin was not measured.

The hypertensive status prior to admission was based upon office BP and an ambulatory BP monitoring was not performed. Hence, it remains uncertain whether he had a truly masked hypertension (undetected established hypertension). However, after the COVID-19 infection and discharge from hospital, he showed worsening of hypertension with a sustained elevated BP. This observation is in line with current attention to the possibility that COVID-19 may lead to permanent or semipermanent post-COVID sequelae [2] . A 24-hour ambulatory BP monitoring should be performed to evaluate patient's true hypertensive state in previously apparently normotensive patients and BP control in patients with known hypertension. A close follow-up with optimal antihypertensive treatment is crucial to avoid long-term cardiovascular complications in these patients.

The prognostic value of newly detected persistently elevated BP following hospitalization for COVID-19 infection should be explored in prospective studies in the future. Finally, the normalization of systolic pulmonary artery pressure measured by echocardiography was also an interesting finding. Acute respiratory failure/ARDS, inflammation, ischemia and vasculitis may be reasons for pulmonary hypertension in COVID-19 patients. Although right ventricular dysfunction and dilatation per se are markers of poor outcome [10, 11] , studies assessing the prognostic value of systolic pulmonary artery pressure regression are warranted.

COVID-19 patients may undergo several hemodynamic changes during hospitalization affecting their BP level. In case of persistently elevated/fluctuating BP values in the clinic, an ambulatory BP monitoring should be performed to evaluate hypertension state, assess BP control and detect other risk features of 24-hour BP, such as nondipping pattern, nocturnal hypertension and morning surge, as well as assess heart rate response. The optimization of antihypertensive treatment and close follow-up at hypertension clinic is essential to achieve BP control and avoid hypertension-induced target organ damage in these vulnerable patients. Case Report

• Acute cardiovascular complications in COVID-19 infection are common and include acute cardiac injury/COVID cardiomyopathy, thromboembolic complications, stroke and arrhythmias. • Post-COVID-sequelae such as sustained elevated blood pressure, sinus tachycardia at rest, poor diabetic control and persistent renal damage may also occur. • In intubated patients with severe acute respiratory distress syndrome, prone positioning contributes to significant improvement of arterial oxygenation and reduces the need for supplemental oxygen. • In case of persistently elevated blood pressure and higher resting heart rate after recovery from COVID-19, an ambulatory blood pressure monitoring should be performed to evaluate patient's true hypertensive state, assess blood pressure control and detect nondipping blood pressure pattern and nocturnal hypertension.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

The case report was internally reviewed and approved by the Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. A written informed consent was obtained from the patient with regard to publication of the case report and any accompanying images.

All data relevant to the study are included in the article. Upon a reasonable request, the authors will make the data, methods used in the analysis available to any researcher for purposes of reproducing the results or replicating the procedure.

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Coronavirus disease 2019 and cardiovascular complications: focused clinical review

This imaging-based clinical review gives a detailed overview of cardiovascular complications in COVID-19 infection

The European Society for Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic

The variety of cardiovascular presentations of COVID-19

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

According to this large population-based study, there was no evidence of an increased or reduced risk of ICU admission with use of renin-angiotensin-aldosterone system blockers

Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; Task Force for the Management of Arterial Hypertension of the European Society of Cardiology

These are the current European Society of Cardiology and European Society of Hypertension guidelines on the management of hypertension in adults

Beneficial effect of awake prone position in hypoxaemic patients with COVID-19: case reports and literature review

Conscious proning: an introduction of a proning protocol for nonintubated, awake, hypoxic emergency department COVID-19 patients

Hyperreninemia and low total body water may contribute to acute kidney injury in COVID-19 patients in intensive care unit